@article {Tetz699, author = {George Tetz and Kristina Kardava and Tatyana Gembitskaya and Maria Vecherkovskaya and Victor Tetz}, title = {Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis}, volume = {56}, number = {suppl 64}, elocation-id = {699}, year = {2020}, doi = {10.1183/13993003.congress-2020.699}, publisher = {European Respiratory Society}, abstract = {FAST-T is a culture-based test system employing new algorithms and enabling the selection of effective antibiotics (Abx) even for polymicrobial drug-resistant infections in cystic fibrosis (CF) patients. It is a multi-well plate filled with novel FASM nutrient medium enabling rapid simultaneous growth of different bacteria in the form of mixed biofilm. In this method (i) Clinical specimen is directly added to the FASM in each well, (ii) some wells contain FASM medium with ABX (1 well contains 1 Abx) taken at concentrations that can be achieved at the site of infection, and (iii) control wells - Abx free medium.Methods: 6-y longitudinal study with 10 patients with CF. We compared the efficacy of antibiotics selected with the use of standard antibiotic susceptibility methods and Abx selected with FAST-T.Results: When ABXs were selected with standard methods, the Median Number of hospitalizations in 3 years was around 6 (of which 3 were required prophylactic hospitalizations). After Abx were selected with FAST-T, the number of hospitalizations was only 1 a year and it was only a required prophylactic one. After the treatment with FAST-T, white blood cell count (WBC) was normalized in 30\% of patients and C-reactive protein (CRP) only in 10\%. In turn, once antibiotic selection switched to FAST-T, both WBC and CRP were normalized in 100\% patients. What{\textquoteright}s more, on year 2 and 3 of FAST-T usage the levels of these pro-inflammatory markers were not anymore elevated. These patients had no signs of an acute inflammation (p\<0.001\%).FAST-T generates phenotype-based Abx selection, enabling the selection of significantly more effective antibiotics.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 699.This abstract was presented at the 2020 ERS International Congress, in session {\textquotedblleft}Respiratory viruses in the "pre COVID-19" era{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/56/suppl_64/699}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }